|
|
替格瑞洛对急性心肌梗死患者心肌细胞保护作用的研究现状及进展
|
Abstract:
急性心肌梗死(AMI)是由于冠状动脉血供急剧减少或中断，使相应心肌因持久性缺血而发生局部坏死。该病具有极高的发病率和死亡率，严重威胁着患者的健康状况。即使AMI患者及时接受介入治疗，心肌细胞的损伤和死亡仍然存在，这对患者的预后造成了显著影响。替格瑞洛是一种新型的P2Y12受体拮抗剂，其通过可逆、非竞争性地结合血小板表面的P2Y12受体，有效地抑制了血小板的活性。近年来的研究表明，替格瑞洛不仅能够通过抑制血小板聚集来改善冠状动脉的血流，还可以通过多种途径直接或间接地保护心肌细胞，因此成为了研究的焦点。本研究旨在结合近期国内外发表的相关研究，对替格瑞洛在急性心肌梗死患者心肌细胞保护作用方面的研究现状及进展进行综述。
Acute myocardial infarction (AMI) is caused by a rapid reduction or interruption of coronary artery blood supply, leading to local necrosis of the corresponding myocardium due to persistent ischemia. The disease has a very high incidence rate and mortality, which seriously threatens the health of patients. Even if AMI patients receive timely intervention treatment, myocardial cell damage and death still exist, which has a significant impact on the prognosis of patients. Ticagrelor is a novel P2Y12 receptor antagonist that effectively inhibits platelet activity by reversibly and non-competitively binding to the P2Y12 receptor on the surface of platelets. Recent studies have shown that ticagrelor not only improves coronary artery blood flow by inhibiting platelet aggregation, but also directly or indirectly protects myocardial cells through various pathways, making it a focus of research. This study aims to review the current status and progress of research on the cardiomyocyte protective effects of ticagrelor in patients with acute myocardial infarction, based on recent studies published both domestically and internationally.
| [1] | Naghavi, M., Ong, K.L., Aali, A., Ababneh, H.S., Abate, Y.H., Abbafati, C., et al. (2024) Global Burden of 288 Causes of Death and Life Expectancy Decomposition in 204 Countries and Territories and 811 Subnational Locations, 1990-2021: A Systematic Analysis for the Global Burden of Disease Study 2021. The Lancet, 403, 2100-2132. https://doi.org/10.1016/s0140-6736(24)00367-2 |
| [2] | Martin, S.S., Aday, A.W., Almarzooq, Z.I., Anderson, C.A.M., Arora, P., Avery, C.L., et al. (2024) 2024 Heart Disease and Stroke Statistics: A Report of US and Global Data from the American Heart Association. Circulation, 149, e347-e913. https://doi.org/10.1161/cir.0000000000001209 |
| [3] | 国家心血管病中心, 中国心血管健康与疾病报告编写组. 中国心血管健康与疾病报告2023概要[J]. 中国循环杂志, 2024, 39(7): 625-660. |
| [4] | Thygesen, K., Alpert, J.S., Jaffe, A.S., Chaitman, B.R., Bax, J.J., Morrow, D.A., et al. (2018) Fourth Universal Definition of Myocardial Infarction (2018). Circulation, 138, e618-e651. https://doi.org/10.1161/cir.0000000000000617 |
| [5] | 董磊, 江新泉. 急性心肌梗死的发病机制及诊疗研究进展[J]. 山东第一医科大学(山东省医学科学院)学报, 2021, 42(6): 476-480. |
| [6] | 中华医学会心血管病学分会, 中华心血管病杂志编辑委员会. 急性ST段抬高型心肌梗死诊断和治疗指南(2019) [J]. 中华心血管病杂志, 2019, 47(10): 766-783. |
| [7] | Giantini, A., Timan, I.S., Dharma, R., Sukmawan, R., Setiabudy, R., Alwi, I., et al. (2023) The Role of Clopidogrel Resistance-Related Genetic and Epigenetic Factors in Major Adverse Cardiovascular Events among Patients with Acute Coronary Syndrome after Percutaneous Coronary Intervention. Frontiers in Cardiovascular Medicine, 9, Article ID: 1027892. https://doi.org/10.3389/fcvm.2022.1027892 |
| [8] | Yang, J., Zhang, R., Liu, Q., Bai, Y., Zhang, L., He, T., et al. (2024) Comparison of Clopidogrel and Ticagrelor in Treating Acute Coronary Syndrome Undergoing PCI: A Systematic Review and Meta-Analysis. Heliyon, 10, e26553. https://doi.org/10.1016/j.heliyon.2024.e26553 |
| [9] | Rao, S.V., O’donoghue, M.L., Ruel, M., et al. (2025) 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients with Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 151, e771-e862. |
| [10] | 刘家超, 李晚泉, 曾小茹, 等. 替格瑞洛对急诊介入治疗心肌梗死的心肌保护作用探讨[J]. 现代消化及介入诊疗, 2019(A1): 443. |
| [11] | 《腺苷注射液在心血管疾病诊疗中的临床应用中国专家共识》专家组. 腺苷注射液在心血管疾病诊疗中的临床应用中国专家共识[J]. 中华心血管病杂志(网络版), 2024, 7(1): 1-13. |
| [12] | 刘毅龙. 替格瑞洛对急性心肌梗死患者心肌灌注的改善作用及安全性评价[D]: [硕士学位论文]. 西安: 西安医学院, 2019. |
| [13] | Armstrong, D., Summers, C., Ewart, L., Nylander, S., Sidaway, J.E. and van Giezen, J.J.J. (2014) Characterization of the Adenosine Pharmacology of Ticagrelor Reveals Therapeutically Relevant Inhibition of Equilibrative Nucleoside Transporter 1. Journal of Cardiovascular Pharmacology and Therapeutics, 19, 209-219. https://doi.org/10.1177/1074248413511693 |
| [14] | 李悦, 陶娌娜, 曹雪, 等. 替格瑞洛的药理作用、生物学效应及不良反应研究进展[J]. 中国药业, 2019, 28(8): 94-97. |
| [15] | 阙斌, 聂绍平, 王春梅, 等. 替格瑞洛对急诊介入治疗心肌梗死的心肌保护作用[J]. 临床心血管病杂志, 2015, 31(11): 1171-1174. |
| [16] | Birnbaum, Y., Ling, S., Nanhwan, M.K., Kodakandla, M. and Ye, Y. (2014) Ticagrelor, but Not Clopidogrel, Protects the Heart and Limits Myocardial Infarct Size. Journal of the American College of Cardiology, 63, A22. https://doi.org/10.1016/s0735-1097(14)60022-x |
| [17] | 王梓, 李晓烨, 吕迁洲. 替格瑞洛升高腺苷浓度引起的生物学效应和不良反应研究进展[J]. 中国新药与临床杂志, 2016, 35(9): 631-634. |
| [18] | Nylander, S., Femia, E.A., Scavone, M., Berntsson, P., Asztély, A., Nelander, K., et al. (2013) Ticagrelor Inhibits Human Platelet Aggregation via Adenosine in Addition to P2Y12 Antagonism. Journal of Thrombosis and Haemostasis, 11, 1867-1876. https://doi.org/10.1111/jth.12360 |
| [19] | 吕莎, 何姝槿, 刘伟, 等. 内皮型一氧化氮合酶异常信号系统调节与动脉粥样硬化防治研究进展[J]. 上海医学, 2018, 41(9): 562-567. |
| [20] | Vilahur, G., Gutiérrez, M., Casani, L., Varela, L., Capdevila, A., Pons-Lladó, G., et al. (2016) Protective Effects of Ticagrelor on Myocardial Injury after Infarction. Circulation, 134, 1708-1719. https://doi.org/10.1161/circulationaha.116.024014 |
| [21] | 何尤夫, 刘微, 刘德斌, 等. 替格瑞洛通过AKT/AMPK/eNOS信号通路调节AMI后小鼠血管新生及其机制研究[J]. 贵州医药, 2024, 48(4): 507-513+519+673. |
| [22] | 徐承义, 苏晞. 直接经皮冠状动脉介入术中心肌再灌注损伤的机制与治疗策略[J]. 内科急危重症杂志, 2017, 23(3): 254-258. |
| [23] | Hausenloy, D. (2004) New Directions for Protecting the Heart against Ischaemia-Reperfusion Injury: Targeting the Reperfusion Injury Salvage Kinase (Risk)-Pathway. Cardiovascular Research, 61, 448-460. https://doi.org/10.1016/j.cardiores.2003.09.024 |
| [24] | Li, G., Ma, D. and Chen, Y. (2016) Cellular Functions of Programmed Cell Death 5. Biochimica et Biophysica Acta (BBA)—Molecular Cell Research, 1863, 572-580. https://doi.org/10.1016/j.bbamcr.2015.12.021 |
| [25] | 王晓妍. 替格瑞洛对心脏血流动力学及心脏缺血再灌注损伤的影响[D]: [硕士学位论文]. 石家庄: 河北医科大学, 2021. |
| [26] | 马婷婷, 郭佳宝, 胡友成, 等. MAMs在心肌缺血再灌注损伤相关细胞凋亡中的研究进展[J]. 心脏杂志, 2025(4): 459-464. |
| [27] | 李昕耘. 替格瑞洛改善急性ST段抬高型心肌梗死病人PCI术后预后的真实世界研究及其抑制缺氧/复氧诱导心肌细胞凋亡的机制研究[D]: [博士学位论文]. 济南: 山东大学, 2021. |
| [28] | 房方, 王国宏, 白英. 血小板在心肌梗死后炎症中作用机制的研究进展[J]. 北京医学, 2024, 46(2): 153-156. |
| [29] | Zhuang, Q., Li, M., Hu, D. and Li, J. (2024) Recent Advances in Potential Targets for Myocardial Ischemia Reperfusion Injury: Role of Macrophages. Molecular Immunology, 169, 1-9. https://doi.org/10.1016/j.molimm.2024.02.007 |
| [30] | 付振强, 安松涛, 孙国举, 等. 急性心肌梗死PCI术后HF患者外周血NLRP3、Caspase-1、IL-1β的表达及意义[J]. 分子诊断与治疗杂志, 2024, 16(11): 2130-2134. |
| [31] | Sandanger, Ø., Ranheim, T., Vinge, L.E., Bliksøen, M., Alfsnes, K., Finsen, A.V., et al. (2013) The NLRP3 Inflammasome Is Up-Regulated in Cardiac Fibroblasts and Mediates Myocardial Ischaemia-Reperfusion Injury. Cardiovascular Research, 99, 164-174. https://doi.org/10.1093/cvr/cvt091 |
| [32] | 宋占春, 陈亮, 何廉旗, 等. 替格瑞洛对急性心肌梗死小鼠心肌的保护作用及机制研究[J]. 重庆医学, 2022, 51(19): 3253-3260. |
| [33] | 麻兴华, 王宪沛, 高传玉. 核因子-κB介导心肌缺血再灌注损伤机制的研究进展[J]. 中华实用诊断与治疗杂志, 2017, 31(1): 88-91. |
| [34] | 陈佩儿, 陈灿, 何原, 等. 替格瑞洛改善心肌缺血再灌注损伤的机制[J]. 实用医学杂志, 2020, 36(16): 2183-2188. |
| [35] | 张承花, 陈静波, 李建文, 等. 替格瑞洛用于急性心肌梗死经皮冠状动脉介入围术期对冠状动脉血流和炎症反应及心肌酶谱的影响[J]. 中国医药, 2021, 16(5): 661-665. |
| [36] | 张立敏, 王伟群, 张明亮, 等. 替格瑞洛及氯吡格雷对经皮冠状动脉介入治疗急性非ST段抬高型心肌梗死患者炎性因子的影响[J]. 中国老年学杂志, 2018, 38(9): 2066-2067. |
| [37] | 梁丽萍, 艾力曼·马合木提, 侯月梅. 氧化应激在心血管疾病中的研究进展[J]. 中国医药, 2015, 10(3): 435-437. |
| [38] | Hausenloy, D.J. and Yellon, D.M. (2013) Myocardial Ischemia-Reperfusion Injury: A Neglected Therapeutic Target. Journal of Clinical Investigation, 123, 92-100. https://doi.org/10.1172/jci62874 |
| [39] | 吴路路, 史生金, 李嘉伟, 等. 替格瑞洛联合PCI治疗老年急性心肌梗死对患者氧化应激损伤心功能及不良心血管事件发生的影响[J]. 河北医学, 2024, 30(4): 586-592. |
| [40] | 朱艳, 徐谭, 贾林霞, 等. 替格瑞洛在NSTEMI病人PCI术后的应用效果及对氧化应激相关因子和内皮功能的影响[J]. 中西医结合心脑血管病杂志, 2020, 18(2): 284-287. |
